Repeated Arterial Occlusion,Delta-Opioid Receptor (DOR) Plasticity and Vagal Transmission Within the Sinoatrial Node of the Anesthetized Dog

Abstract

Brief interruptions in coronary blood flow precondition the heart, engage delta-opioid receptor (DOR) mechanisms and reduce the damage that typically accompanies subsequent longer coronary occlusions. Repeated short occlusions of the sinoatrial (SA) node artery progressively raised nodal methionine-enkephalin-arginine-phenylalanine (MEAP) and improved vagal transmission during subsequent long occlusions in anesthetized dogs. The DOR type-1 (DOR-1) antagonist, BNTX reversed the vagotonic effect. Higher doses of enkephalin interrupted vagal transmission through a DOR-2 mechanism. The current study tested whether the preconditioning (PC) protocol, the later occlusion or a combination of both was required for the vagotonic effect. The study also tested whether evolving vagotonic effects included withdrawal of competing DOR-2 vagolytic influences. Vagal transmission progressively improved during successive SA nodal artery occlusions. The vagotonic effect was absent in sham animals and after DOR-1 blockade. After completing the PC protocol, exogenously applied vagolytic doses of MEAP reduced vagal transmission under both normal and occluded conditions. The magnitude of these DOR-2 vagolytic effects was small compared to controls and repeated MEAP challenges rapidly eroded vagolytic responses further. Prior DOR-1 blockade did not alter the PC mediated, progressive loss of DOR-2 vagolytic responses. In conclusion, DOR-1 vagotonic responses evolved from signals earlier in the PC protocol and erosion of competing DOR-2 vagolytic responses may have contributed to an unmasking of vagotonic responses. The data support the hypothesis that PC and DOR-2 stimulation promote DOR trafficking, and down regulation of the vagolytic DOR-2 phenotype in favor of the vagotonic DOR-1 phenotype. DOR-1 blockade may accelerate the process by sequestering newly emerging receptors.

Get full access to this article

View all access options for this article.

References

Allouche S, Hasbi A, Ferey V, Sola B, Jauzak P, Polastron J. Pharmacological α-1 and α-2 opioid receptor subtypes in the human neuroblastoma cell line SK-N-BE: no evidence for distinct molecular entities. Biochem Pharmacol 59:915–925, 2000.

Bao L, Jin SX, Zhang C, Wang LH, Xu ZZ, Zhang FX, Wang LC, Ning FS, Cai HJ, Guan JS, Xiao HS, Xu ZQ, He C, Hökfelt T, Zhou Z, Zhang X. Activation of delta opioid receptors induces receptor insertion and neuropeptide secretion. Neuron 37(1):121–33, 2003.

Billman GE, Schwartz PJ, Stone HL. The effects of daily exercise on susceptibility to sudden cardiac death. Circulation 69(6):1182–1189, 1984.

Binkley PF, Nunziata E, Haas GJ, Nelson SD, Cody RJ. Parasympathetic withdrawal is an integral component of autonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 18(2):464–472, 1991.

Brown DA, Moore RL. Perspectives in innate and acquired cardioprotection: cardioprotection acquired through exercise. J Appl Physiol 103(5):1894–1899, 2007.

Caffrey JL, Mateo Z, Napier LD, Gaugl JF, Barron BA. Intrinsic cardiac enkephalins inhibit vagal bradycardia in the dog. Am J Physiol 268(2 Pt 2):H848–H855, 1995.

Crain SM, Shen KF. After chronic opioid exposure sensory neurons become supersensitive to the excitatory effects of opioid agonists and antagonists as occurs after acute elevation of GM1 ganglioside. Brain Res 575(1):13–24, 1992.

Cvejic S, Devi LA. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J Biol Chem 272(43):26959–26964, 1997.

Davis S, Deo SH, Barlow M, Yoshishige D, Farias M, Caffrey JL. The monosialosyl ganglioside GM-1 reduces the vagolytic efficacy of delta2-opioid receptor stimulation. Am J Physiol Heart Circ Physiol 291(5):H2318–H2326, 2006.

10.

Deo SH, Barlow MA, Gonzalez L, Yoshishige Y, Caffrey JL. Cholinergic location of delta opioid receptors in canine atria and SA node. Am J Physiol Heart Circ Physiol 294:H829–H838, 2008.

11.

Deo SH, Johnson-Davis S, Barlow MA, Yoshishige D, Caffrey JL. Repeated delta1-opioid receptor stimulation reduces delta2-opioid receptor responses in the SA node. Am J Physiol Heart Circ Physiol 291(5):H2246–H2254, 2006.

12.

Dickson EW, Hogrefe CP, Ludwig PS, Ackermann LW, Stoll LL, Denning GM. Exercise enhances myocardial ischemic tolerance via an opioid receptor-dependent mechanism. Am J Physiol Heart Circ Physiol 294:H402–H408, 2008.

13.

Dickson EW, Ludwig PS, Ackermann LW, Buresh CT, Denning GM. Met5-enkephalin-Arg6-Phe7 (MEAP): a cardioprotective hormonal opioid. Acad Emerg Med 13:813–819, 2006.

14.

Farias M 3rd, Jackson K, Johnson M, Caffrey JL. Cardiac enkephalins attenuate vagal bradycardia: interactions with NOS-1-cGMP systems in canine sinoatrial node. Am J Physiol Heart Circ Physiol 285(5):H2001–H2012, 2003.

15.

Farias M 3rd, Jackson KE, Yoshishige D, Caffrey JL. Cardiac enkephalins interrupt vagal bradycardia via delta 2-opioid receptors in sinoatrial node. Am J Physiol Heart Circ Physiol 284(5):H1693–H1701, 2003.

16.

Farias M, Jackson K, Stanfill A, Caffrey JL. Local opiate receptors in the sinoatrial node moderate vagal bradycardia. Auton Neurosci 87(1): 9–15, 2001.

17.

Farias M, Jackson K, Yoshishige D, Caffrey JL. Bimodal delta-opioid receptors regulate vagal bradycardia in canine sinoatrial node. Am J Physiol Heart Circ Physiol 285(3):H1332–H1339, 2003.

18.

Gross GJ. Role of opioids in acute and delayed preconditioning. J Mol Cell Cardiol 35(7):709–718, 2003.

19.

Howells RD, Kilpatrick DL, Bailey LC, Noe M, Udenfriend S. Proenkephalin mRNA in rat heart. Proc Natl Acad Sci U S A 83(6): 1960–1963, 1986.

20.

Jackson KE, Farias M, Stanfill A, Caffrey JL. Delta opioid receptors inhibit vagal bradycardia in the sinoatrial node. J Cardiovasc Pharmacol Ther 6(4):385–393, 2001.

21.

Jackson KE, Farias M, Stanfill AS, Caffrey JL. Transient arterial occlusion raises enkephalin in the canine sinoatrial node and improves vagal bradycardia. Auton Neurosci 94(1–2):84–92, 2001.

22.

Keren O, Gafni M, Sarne Y. Opioids potentiate transmitter release from SK-N-SH human neuroblastoma cells by modulating N-type calcium channels. Brain Res 764(1–2):277–282, 1997.

23.

Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59(4):256–262, 1987.

24.

Kuzume K, Wolff RA, Amakawa K, Kuzume K, Van Winkle DM. Sustained exogenous administration of Met5-enkephalin protects against infarction in vivo. Am J Physiol Heart Circ Physiol 285(6): H2463–H2470, 2003.

25.

Lang RE, Hermann K, Dietz R, Gaida W, Ganten D, Kraft K, Unger T. Evidence for the presence of enkephalins in the heart. Life Sci 32(4): 399–406, 1983.

26.

Loh HH, Smith AP. Molecular characterization of opioid receptors. Annu Rev Pharmacol Toxicol 30:123–147, 1990.

27.

Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74(5): 1124–1136, 1986.

28.

Paradis P, Dumont M, Belichard P, Rouleau JL, Lemaire S, Brakier-Gingras L. Increased preproenkephalin A gene expression in the rat heart after induction of a myocardial infarction. Biochem Cell Biol 70(7):593–598, 1992.

29.

Portoghese PS, Sultana M, Nagase H, Takemori AE. A highly selective delta 1-opioid receptor antagonist: 7-benzylidenenaltrexone. Eur J Pharmacol 218(1):195–196, 1992.

30.

Przyklenk K, Darling CE, Dickson EW, Whittaker P. Cardioprotection ‘outside the box’—the evolving paradigm of remote preconditioning. Basic Res Cardiol 98(3):149–157, 2003.

31.

Sarne Y, Fields A, Keren O, Gafni M. Stimulatory effects of opioids on transmitter release and possible cellular mechanisms: overview and original results. Neurochem Res 21(11):1353–1361, 1996.

32.

Schallmach E, Steiner D, Vogel Z. Adenylyl cyclase type II activity is regulated by two different mechanisms: implications for acute and chronic opioid exposure. Neuropharmacology 50(8):998–1005, 2006.

33.

Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation 97(13):1282–1289, 1998.

34.

Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 78(6):1100–1104, 1996.

35.

Schultz JE, Rose E, Yao Z, Gross GJ. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts. Am J Physiol 268(5 Pt 2):H2157–H2161, 1995.

36.

Springhorn JP, Claycomb WC. Translation of heart preproenkephalin mRNA and secretion of enkephalin peptides from cultured cardiac myocytes. Am J Physiol 263(5 Pt 2):H1560–H1566, 1992.

37.

Van Wylen DG, Willis J, Sodhi J, Weiss RJ, Lasley RD, Mentzer RM Jr. Cardiac microdialysis to estimate interstitial adenosine and coronary blood flow. Am J Physiol 258(6 Pt 2):H1642–H1649, 1990.

38.

Whistler JL, Tsao P, von Zastrow M. A phosphorylation-regulated brake mechanism controls the initial endocytosis of opioid receptors but is not required for post-endocytic sorting to lysosomes. J Biol Chem 276(36):34331–34338, 2001.

39.

Yao Z, Gross GJ. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol 264(6 Pt 2): H2221–H2225, 1993.

40.

Younes A, Pepe S, Barron BA, Spurgeon HA, Lakatta EG, Caffrey JL. Cardiac synthesis, processing, and coronary release of enkephalin-related peptides. Am J Physiol Heart Circ Physiol 279(4):H1989–H1998, 2000.

41.

Younes A, Pepe S, Yoshishige D, Caffrey JL, Lakatta EG. Ischemic preconditioning increases the bioavailability of cardiac enkephalins. Am J Physiol Heart Circ Physiol 289(4):H1652–H1661, 2005.

42.

Warner MR, Zipes DP. Vagal control of myocardial refractoriness. In: Levy MN, Schwartz PJ, Eds. Vagal Control of the Heart. Armonk, New York: Futura Publishing Co., pp261–273, 1994.

43.

Barlow MA, Deo SH, Gonzalez L, Caffrey JL. Delta receptor phenotypes and vascular conductance in skeletal muscle. FASEB J 21:957.7, 2007 (Abstract).

44.

Barlow MA, Deo S, Johnson-Davis S, Caffrey JL. Vagotonic effects of enkephalin are not mediated by sympatholytic mechanisms. Exp Biol Med 231:387–395, 2006.

45.

Stanfill, AA, Jackson KE, Farias M, Barlow M, Deo, S, Johnson S, JL Caffrey. Leucine-enkephalin interrupts sympathetically mediated tachycardia prejunctionally in the canine sinoatrial node. Exp Biol Med 228:898–906, 2003.

46.

Peart, JN, Patel HH, Gross GJ. Delta-opioid receptor activation mimics ischemic preconditioning in the canine heart. J Cardiovasc Pharmacol 42:78–81, 2003.